Articles

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050 a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Cancer Collaborators. Lancet. 2025 Oct 11;406(10512):1565-1586

In 2023, excluding non-melanoma skin cancers, there were 18·5 million incident cases of cancer and 10·4 million deaths, contributing to 271 million DALYs globally. Of these, 57·9% of incident cases and 65·8% of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group c... Read More

12 May, 2026

Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Breast Cancer Collaborators. Lancet Oncol. 2026 Mar;27(3):302-326

Breast cancer is a leading cause of mortality and morbidity among females worldwide. In 2023, there were an estimated 2.30 million breast cancer incident cases, 764 000 deaths, and 24.1 million DALYs among females globally. In the World Bank low-income group, where a low age-standardised incidence rate (ASIR) was ... Read More

12 May, 2026

A Population-Based Study of Genes Previously Implicated in Breast Cancer

Chunling Hu, Steven N Hart, Rohan Gnanaolivu et al. N Engl J Med. 2021 Feb 4;384(5):440-451

In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Can... Read More

15 Apr, 2026

Tissue-agnostic cancer therapies: promise, reality, and the path forward

Vivek Subbiah. Nature Communications. (2025) 16:4972

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting moleculardrivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progressdepends on universal genomic testing, an oncoge... Read More

15 Apr, 2026

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P Patel, Megan Othus, Yuanbin Chen et al. N Engl J Med. 2023 Mar 2;388(9):813-823

In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (2... Read More

15 Apr, 2026

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Christian U Blank, Minke W Lucas, Richard A Scolyer et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708

In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, th... Read More

15 Apr, 2026

Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation

Oliver Langselius , Harriet Rumgay, Esther de Vries, David C Whiteman et al. Int J Cancer. 2025 Sep 15;157(6):1110-1119

Cutaneous melanoma (CM) accounted for around 331,700 cancer cases globally in 2022. Ultraviolet radiation (UVR) is a major CM risk factor. In this study, we update and improve global estimates of UVR-attributable CM cases. An estimated 267,353 CM cases were UVR attributable globally in 2022. Males contributed to a larg... Read More

15 Apr, 2026

Global in cutaneous malignant melanoma incidence and mortality

Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, et al. Melanoma Res. 2024 Jun 1;34(3):265-275

Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries. However, incidence has been increasing in several countries. Mortality from CMM in all age groups showed a favorable pattern in the majority of the countries consid... Read More

15 Apr, 2026

Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review

Xia Wei, Samuel Oxley, Ranjit Manchanda et al. Cancers 2022, 14, 6117

This systematic review found that surgical prevention is cost-effective for women in high-income countries who are at a high risk of breast cancer, intermediate/high risk of ovarian cancer and high risk of endometrial cancer. Synthesized cost-effectiveness evidence is necessary for resource allocation for risk-reducing... Read More

15 Apr, 2026

The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes

Rami James N Aoun and Matthew F Kalady. Surg Oncol. 2022 Aug: 43:101765

Approximately 5% of colorectal cancers arise within an inherited colorectal cancer syndrome, with known underlying genetic etiologies. These syndromes increase the risk of colorectal and extracolonic cancers. Identification of a specific genetic pathogenic variant defines the syndrome, and quantifies the elevated risks... Read More

15 Apr, 2026